10605-66-0

Usage

Uses

Used in Chemical Synthesis:
4-methylpent-2-yne-1,4-diol is used as a chemical intermediate for the synthesis of other organic compounds, leveraging its reactivity to form a wide range of products.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 4-methylpent-2-yne-1,4-diol is utilized as a starting material for the production of various pharmaceuticals, contributing to the development of new drugs and medicinal compounds.
Used in Coatings and Adhesives:
4-methylpent-2-yne-1,4-diol is employed as a component in the formulation of coatings and adhesives, enhancing their performance and properties due to its reactive nature.
Used in Polymer Preparation:
As a starting material in the preparation of various polymers, 4-methylpent-2-yne-1,4-diol plays a crucial role in the advancement of materials science, with potential applications in diverse fields such as plastics, textiles, and composite materials.
Used in Materials Science and Engineering:
4-methylpent-2-yne-1,4-diol is applied in the field of materials science and engineering for the development of innovative materials with improved properties, such as enhanced strength, flexibility, or chemical resistance.

InChI:InChI=1/C6H10O2/c1-6(2,8)4-3-5-7/h7-8H,5H2,1-2H3

Upstream product

• 107-19-7 propargyl alcohol 
• 67-64-1 acetone 
• 50-00-0 formaldehyd 
• 115-19-5 2-methyl-but-3-yn-2-ol 
• 14092-32-1 2-methyl-5-<(tetrahydro-2H-pyran-2-yl)-oxy>-3-pentyn-2-ol 
• 13030-38-1 5-(1-butoxy-ethoxy)-2-methyl-pent-3-yn-2-ol 
• 259880-64-3 5-{[tert-butyl(dimethyl)silyl]oxy}-2-methylpent-3-yn-2-ol 
• 925-90-6 ethylmagnesium bromide 

Downstream Products

• 3132-22-7 5,5-dimethyldihydrofuran-3(2H)-one 
• 167100-91-6 2-methyl-5-tosyloxy-3-pentyn-2-ol 
• 1601497-20-4 4-methyl-2-phenylpenta-2,3-dien-1-ol 
• 1422127-87-4 C₂₄H₂₅F₆N₃O₂S 
• 1003-17-4 2,2-dimethyltetrahydrofuran 
• 902451-94-9 (2S,3S)-Toluene-4-sulfonic acid 2-methyl-3-[3-methyl-3-(tetrahydropyran-2-yloxy)butyl]oxiranylmethyl ester 
• 3123-97-5 dihydro-5,5-dimethyl-2(3H)-furanone 
• 10605-68-2 4-methyl-4-penten-2-yn-1-ol 

Relevant academic research and scientific papers

Synthesis of 8-methylnonane-1,6,7-trien-4-one and related allenes as potentially useful synthetic precursors

The allenic ketone 8-methylnonane-1,6,7-trien-4-one and related allenes have been synthesized from simple commercially available materials. Since allenes analogous to 8-methylnonane-1,6,7-trien-4-one have previously been transformed to substituted bicyclo[3.3.0]octanones via corresponding bicyclo[3.2.0]heptanones, it is anticipated that the present allenic ketone may also undergo similar transformations. Substituted bicyclo[3.3.0]octanones are known synthetic precursors of tricyclic sesquiterpenes. Thus, 8-methylnonane-1,6,7- trien-4-one presents itself as a possible precursor for the synthesis of tricyclopentanoid ring system present in sesquiterpenes such as hirsutene and Δ9(12)-capnellene.

A synthesis of japanese hop ether

Reaction of 2,5-dihydro-2,2-dimethylfuran with ethynehexacarbonyldicobalt lacks significant regioselectivity, but nevertheless makes possible the synthesis of (±)-hop ether (cis-hexahydro-1,1-dimethyl-4-methylene-1H-cyclopenta[c]furan) in five steps from cis-4-methylpent-2-ene-1,4-diol.

Method for Preparing Crosslinker Compound

The present disclosure relates to a method for preparing a crosslinker compound in which a crosslinker compound capable of using for the production of a super absorbent polymer can be obtained in a higher yield by a simple manner. The crosslinker compound obtained by the above method can be used as a thermally decomposable crosslinker in the process of producing a super absorbent polymer.

A novel RET inhibitor. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to a novel RET inhibitor, a pharmaceutical composition and application thereof. In particular, the invention relates to a compound represented by formula (I), a stereoisomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug thereof, I said compound and a pharmaceutical composition thereof for the manufacture of a medicament, in particular for the treatment and prophylaxis and RET of diseases and disorders associated with irritable bowel syndrome.

RET Inhibitor. Pharmaceutical composition and use thereof

The invention belongs to the field of medicines, and relates to a novel RET inhibitor, a pharmaceutical composition and application thereof. , The present invention relates to a compound represented by formula (I), a stereoisomer, a geometric isomer, a tautomer, an oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug thereof, I, and a pharmaceutical composition thereof in the manufacture of a medicament, in particular for the treatment and prevention and RET of diseases and disorders associated with irritable bowel syndrome.

Novel Crosslinking Agent Compound and Superabsorbent Polymer Prepared by Using the Same

Provided are a novel crosslinking agent compound, and a superabsorbent polymer prepared by using the same. More particularly, provided are a crosslinking agent compound having a novel structure, which exhibits excellent crosslinking property and thermal degradability, and a superabsorbent polymer prepared by using the same.

Synthesis of Polysubstituted 2-Iodoindenes via Iodonium-Induced Cyclization of Arylallenes

A new chemoselective iodocarbocyclization of allenyl arenes was developed leading to the formation of 2-iodoindenes. In acetonitrile or nitromethane, electrophilic sources of iodine cations react selectively with the C2-C3 double bond of 1-arylallenes to give, after anti nucleophilic attack of the aromatic ring, 2-iodoindene products in high yields. Variations of the allenic skeletons revealed the high 5-endo selectivity and some competitive pathways of cyclization. Postfunctionalization reactions of the carbon-iodine bond, via Pd- and Cu-cross-couplings, gave rise to substituted indenes in good to excellent yields. (Chemical Equation Presented).

Copper(i) iodide catalyzed synthesis of primary propargylic alcohols from terminal alkyne

A highly efficient and practical method for the synthesis of primary propargylic alcohols has been developed using CuI as catalyst and paraformaldehyde as the formaldehyde source. The reaction was performed under mild reaction conditions offering the desired products in good to excellent yields with a variety of terminal alkynes.

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re', m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE

PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE ABSTRACT OF THE DISCLOSURE The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: {INSERT STRUCTURE HERE} I wherein variables A4, A5, A6, A8, each of Ra, Rb, R1, R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.